Discounted Cash Flow
Novabridge Biosciences ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | — | — | — | — |
| 2017 | $858.0k | $-44.1m | $-37.7m | -5144.3% | $-51.93 |
| 2018 | $53.8m (6168.2%) | $-59.6m (-35.1%) | $-43.7m (-16.0%) | -110.9% (97.8%) | $-61.70 (-18.8%) |
| 2019 | $4.3m (-92.0%) | $-214.9m (-260.4%) | $653.2k (101.5%) | -4986.8% (-4398.6%) | $-28.90 (53.2%) |
| 2020 | $236.4m (5386.7%) | $69.7m (132.4%) | $1.1m (72.4%) | 29.5% (100.6%) | $0.54 (101.9%) |
| 2021 | $13.8m (-94.2%) | $-345.1m (-595.1%) | $2.1m (83.6%) | -2498.1% (-8574.3%) | $-2.09 (-487.0%) |
| 2022 | $-32.1m (-332.6%) | $-371.1m (-7.5%) | $4.3m (108.0%) | 1155.1% (146.2%) | $-0.74 (64.6%) |
| 2023 | $3.9m (112.1%) | $-216.9m (41.5%) | $3.0m (-29.5%) | -5571.9% (-582.4%) | $-0.43 (41.9%) |
| 2024 | $7.5m (92.3%) | $-3.3m (98.5%) | $112.0k (-96.3%) | -43.9% (99.2%) | $-0.27 (37.2%) |
| 2025 | $7.6m (1.7%) | $-6.8m (-108.1%) | $148.6k (32.6%) | -90.0% (-104.7%) | $-0.21 (22.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in CNY. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.